Cargando…

Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study

BACKGROUND: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for posto...

Descripción completa

Detalles Bibliográficos
Autores principales: Jingu, Keiichi, Matsushita, Haruo, Takeda, Ken, Umezawa, Rei, Takahashi, Chiaki, Sugawara, Toshiyuki, Kubozono, Masaki, Abe, Keiko, Tanabe, Takaya, Shirata, Yuko, Yamamoto, Takaya, Ishikawa, Youjirou, Nemoto, Kenji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518148/
https://www.ncbi.nlm.nih.gov/pubmed/23171077
http://dx.doi.org/10.1186/1471-2407-12-542
_version_ 1782252524856672256
author Jingu, Keiichi
Matsushita, Haruo
Takeda, Ken
Umezawa, Rei
Takahashi, Chiaki
Sugawara, Toshiyuki
Kubozono, Masaki
Abe, Keiko
Tanabe, Takaya
Shirata, Yuko
Yamamoto, Takaya
Ishikawa, Youjirou
Nemoto, Kenji
author_facet Jingu, Keiichi
Matsushita, Haruo
Takeda, Ken
Umezawa, Rei
Takahashi, Chiaki
Sugawara, Toshiyuki
Kubozono, Masaki
Abe, Keiko
Tanabe, Takaya
Shirata, Yuko
Yamamoto, Takaya
Ishikawa, Youjirou
Nemoto, Kenji
author_sort Jingu, Keiichi
collection PubMed
description BACKGROUND: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer. METHODS: Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m(2)/2 h) and 5-FU (500 mg/m(2)/24 h for 5 days). The primary endpoint was overall survival rate, and the secondary endpoints were progression-free survival rate, irradiated-field control rate and chronic toxicity. RESULTS: A total of 30 patients were enrolled in this study. The regimen was completed in 76.7% of the patients. The median observation period for survivors was 72.0 months. The 5-year overall survival rate was 27.0% with a median survival period of 21.0 months. The 5-year progression-free survival rate and irradiated-field control rate were 25.1% and 71.5%, respectively. Grade 3 or higher late toxicity was observed in only one patient. Two long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy. Pretreatment performance status, pattern of recurrence (worse for patients with anastomotic recurrence) and number of recurrent lesions (worse for patients with multiple recurrent lesions) were statistically significant prognostic factors for overall survival. CONCLUSIONS: Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative loco-regional recurrent esophageal cancer. However, the prognosis of patients with multiple regional recurrence or anastomotic recurrence is very poor.
format Online
Article
Text
id pubmed-3518148
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35181482012-12-11 Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study Jingu, Keiichi Matsushita, Haruo Takeda, Ken Umezawa, Rei Takahashi, Chiaki Sugawara, Toshiyuki Kubozono, Masaki Abe, Keiko Tanabe, Takaya Shirata, Yuko Yamamoto, Takaya Ishikawa, Youjirou Nemoto, Kenji BMC Cancer Research Article BACKGROUND: In 2006, we reported the effectiveness of chemoradiotherapy for postoperative recurrent esophageal cancer with a median observation period of 18 months. The purpose of the present study was to update the results of radiotherapy combined with nedaplatin and 5-fluorouracil (5-FU) for postoperative loco-regional recurrent esophageal cancer. METHODS: Between 2000 and 2004, we performed a phase II study on treatment of postoperative loco-regional recurrent esophageal cancer with radiotherapy (60 Gy/30 fractions/6 weeks) combined with chemotherapy consisting of two cycles of nedaplatin (70 mg/m(2)/2 h) and 5-FU (500 mg/m(2)/24 h for 5 days). The primary endpoint was overall survival rate, and the secondary endpoints were progression-free survival rate, irradiated-field control rate and chronic toxicity. RESULTS: A total of 30 patients were enrolled in this study. The regimen was completed in 76.7% of the patients. The median observation period for survivors was 72.0 months. The 5-year overall survival rate was 27.0% with a median survival period of 21.0 months. The 5-year progression-free survival rate and irradiated-field control rate were 25.1% and 71.5%, respectively. Grade 3 or higher late toxicity was observed in only one patient. Two long-term survivors had gastric tube cancer more than 5 years after chemoradiotherapy. Pretreatment performance status, pattern of recurrence (worse for patients with anastomotic recurrence) and number of recurrent lesions (worse for patients with multiple recurrent lesions) were statistically significant prognostic factors for overall survival. CONCLUSIONS: Radiotherapy combined with nedaplatin and 5-FU is a safe and effective salvage treatment for postoperative loco-regional recurrent esophageal cancer. However, the prognosis of patients with multiple regional recurrence or anastomotic recurrence is very poor. BioMed Central 2012-11-22 /pmc/articles/PMC3518148/ /pubmed/23171077 http://dx.doi.org/10.1186/1471-2407-12-542 Text en Copyright ©2012 Jingu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jingu, Keiichi
Matsushita, Haruo
Takeda, Ken
Umezawa, Rei
Takahashi, Chiaki
Sugawara, Toshiyuki
Kubozono, Masaki
Abe, Keiko
Tanabe, Takaya
Shirata, Yuko
Yamamoto, Takaya
Ishikawa, Youjirou
Nemoto, Kenji
Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
title Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
title_full Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
title_fullStr Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
title_full_unstemmed Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
title_short Long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase II study
title_sort long-term bresults of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: update on a phase ii study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518148/
https://www.ncbi.nlm.nih.gov/pubmed/23171077
http://dx.doi.org/10.1186/1471-2407-12-542
work_keys_str_mv AT jingukeiichi longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT matsushitaharuo longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT takedaken longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT umezawarei longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT takahashichiaki longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT sugawaratoshiyuki longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT kubozonomasaki longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT abekeiko longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT tanabetakaya longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT shiratayuko longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT yamamototakaya longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT ishikawayoujirou longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy
AT nemotokenji longtermbresultsofradiotherapycombinedwithnedaplatinand5fluorouracilforpostoperativelocoregionalrecurrentesophagealcancerupdateonaphaseiistudy